, (GLOBE NEWSWIRE) -- (Nasdaq:CYTK) announced today that it is scheduled to report fourth quarter results on at . Following the announcement, Cytokinetics' senior management will host a conference call at to discuss operational and financial results and the company's outlook for the future.

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( and ) or (706) 679-3078 (international) and typing in the passcode 29637209.

An archived replay of the webcast will be available via website until , 2016. The replay will also be available via telephone by dialing (855) 859-2056 ( and ) or (404) 537-3406 (international) and typing in the passcode 29637209 from at until .

About

is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the and orphan medicinal product designation by the for the potential treatment of ALS. retains the right to develop and commercialize tirasemtiv. is collaborating with to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. is collaborating with to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. For additional information about , visit www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the 'Act'). disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the .

Contact:

Vice President, Corporate Communications, Investor Relations
(650) 624-3060

Cytokinetics Incorporated issued this content on 02 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 February 2016 21:19:51 UTC

Original Document: http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-newsArticle&ID=2134921